Compass Therapeutics, Inc.
CMPX
$5.28
$0.061.15%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 850.00K | 850.00K | 850.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 850.00K | 850.00K | 850.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 0.00 | 850.00K | 850.00K | 850.00K |
| SG&A Expenses | 16.09M | 16.73M | 16.80M | 15.13M | 14.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.42M | 67.85M | 62.67M | 57.48M | 56.30M |
| Operating Income | -71.42M | -67.85M | -61.82M | -56.63M | -55.45M |
| Income Before Tax | -65.81M | -62.03M | -55.22M | -49.38M | -47.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.81 | -62.03 | -55.22 | -49.38 | -47.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.81M | -62.03M | -55.22M | -49.38M | -47.76M |
| EBIT | -71.42M | -67.85M | -61.82M | -56.63M | -55.45M |
| EBITDA | -71.02M | -67.32M | -61.25M | -56.04M | -54.84M |
| EPS Basic | -0.46 | -0.45 | -0.40 | -0.36 | -0.36 |
| Normalized Basic EPS | -0.29 | -0.28 | -0.25 | -0.23 | -0.23 |
| EPS Diluted | -0.46 | -0.45 | -0.40 | -0.36 | -0.36 |
| Normalized Diluted EPS | -0.29 | -0.28 | -0.25 | -0.23 | -0.23 |
| Average Basic Shares Outstanding | 581.93M | 550.73M | 550.04M | 548.41M | 533.74M |
| Average Diluted Shares Outstanding | 581.93M | 550.73M | 550.04M | 548.41M | 533.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |